Topical PI3K/mTOR Inhibitor Shows Promise in Proof-Of-Concept AK Study
Bimiralisib gel 2% (Torqur AG) performed well in a Phase 2 proof-of-concept study for the treatment of actinic keratosis (AK), according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France.